by ltsiwpadmin | May 18, 2017 | News
Daniela Semedo, PhD May 18, 2017 Albireo Pharma has secured two new patents from the U.S. Patent and Trademark Office (USPTO) for its lead drug candidate A4250 to treat liver diseases such as nonalcoholic steatohepatitis (NASH). Boston-based Albireo has reported...
by ltsiwpadmin | May 16, 2017 | News
Source: Children’s Hospital Los Angeles Summary A team of investigators has identified key inflammatory cells involved in nonalcoholic fatty liver disease. Current treatment for the disorder involves changes to diet, yet no medication has been approved for...
by ltsiwpadmin | May 16, 2017 | News
Juliet Preston May 16, 2017 A new report by GlobalData has underscored the extreme blockbuster potential of fatty liver disease and non-alcoholic steatohepatitis (NASH), projecting that the current $618 million market will balloon to $25.3 billion by 2026. A new...
by ltsiwpadmin | May 15, 2017 | News
Inês Martins, PhD May 15, 2017 A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced. This is...
Recent Comments